U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Secondary Acute Myeloid Leukemia

MedGen UID:
76113
•Concept ID:
C0280449
•
Neoplastic Process
Synonyms: Secondary Acute Myeloblastic Leukemia; Secondary Acute Myelogenous Leukemia; Secondary AGL; Secondary AML

Definition

An acute myeloid leukemia arising from prior myelodysplastic syndrome, myeloproliferative neoplasm, or myelodysplastic/myeloproliferative neoplasm, or as a result of previous exposure to alkylating agents or topoisomerase II inhibitors. [from NCI]

Professional guidelines

PubMed

Management and Outcomes of Blast Transformed Chronic Myelomonocytic Leukemia.
Hammond D, Montalban-Bravo G
Curr Hematol Malig Rep 2021 Oct;16(5):405-417. Epub 2021 Sep 9 doi: 10.1007/s11899-021-00643-3. PMID: 34499330
Secondary Acute Myeloid Leukemia: A Primary Challenge of Diagnosis and Treatment.
Winer ES
Hematol Oncol Clin North Am 2020 Apr;34(2):449-463. Epub 2020 Jan 7 doi: 10.1016/j.hoc.2019.11.003. PMID: 32089222
Treatment of secondary acute myeloid leukemia.
Pulsoni A, Pagano L
J Clin Oncol 2005 Feb 1;23(4):926-7. doi: 10.1200/JCO.2005.05.202. PMID: 15681547

Recent clinical studies

Etiology

Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution.
Rodriguez-Meira A, Norfo R, Wen S, Chédeville AL, Rahman H, O'Sullivan J, Wang G, Louka E, Kretzschmar WW, Paterson A, Brierley C, Martin JE, Demeule C, Bashton M, Sousos N, Moralli D, Subha Meem L, Carrelha J, Wu B, Hamblin A, Guermouche H, Pasquier F, Marzac C, Girodon F, Vainchenker W, Drummond M, Harrison C, Chapman JR, Plo I, Jacobsen SEW, Psaila B, Thongjuea S, Antony-Debré I, Mead AJ
Nat Genet 2023 Sep;55(9):1531-1541. Epub 2023 Sep 4 doi: 10.1038/s41588-023-01480-1. PMID: 37666991Free PMC Article
A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial.
Othman J, Wilhelm-Benartzi C, Dillon R, Knapper S, Freeman SD, Batten LM, Canham J, Hinson EL, Wych J, Betteridge S, Villiers W, Kleeman M, Gilkes A, Potter N, Overgaard UM, Mehta P, Kottaridis P, Cavenagh J, Hemmaway C, Arnold C, Dennis M, Russell NH
Blood Adv 2023 Aug 22;7(16):4539-4549. doi: 10.1182/bloodadvances.2023010276. PMID: 37171402Free PMC Article
Challenges in the diagnosis and treatment of secondary acute myeloid leukemia.
Ossenkoppele G, Montesinos P
Crit Rev Oncol Hematol 2019 Jun;138:6-13. Epub 2019 Mar 16 doi: 10.1016/j.critrevonc.2019.03.003. PMID: 31092386
MDS overlap disorders and diagnostic boundaries.
Tanaka TN, Bejar R
Blood 2019 Mar 7;133(10):1086-1095. Epub 2019 Jan 22 doi: 10.1182/blood-2018-10-844670. PMID: 30670443
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.
Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Stone RM, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Hoering A, Banerjee K, Chiarella M, Louie AC, Medeiros BC
J Clin Oncol 2018 Sep 10;36(26):2684-2692. Epub 2018 Jul 19 doi: 10.1200/JCO.2017.77.6112. PMID: 30024784Free PMC Article

Diagnosis

A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial.
Othman J, Wilhelm-Benartzi C, Dillon R, Knapper S, Freeman SD, Batten LM, Canham J, Hinson EL, Wych J, Betteridge S, Villiers W, Kleeman M, Gilkes A, Potter N, Overgaard UM, Mehta P, Kottaridis P, Cavenagh J, Hemmaway C, Arnold C, Dennis M, Russell NH
Blood Adv 2023 Aug 22;7(16):4539-4549. doi: 10.1182/bloodadvances.2023010276. PMID: 37171402Free PMC Article
Secondary Acute Myeloid Leukemia: A Primary Challenge of Diagnosis and Treatment.
Winer ES
Hematol Oncol Clin North Am 2020 Apr;34(2):449-463. Epub 2020 Jan 7 doi: 10.1016/j.hoc.2019.11.003. PMID: 32089222
Challenges in the diagnosis and treatment of secondary acute myeloid leukemia.
Ossenkoppele G, Montesinos P
Crit Rev Oncol Hematol 2019 Jun;138:6-13. Epub 2019 Mar 16 doi: 10.1016/j.critrevonc.2019.03.003. PMID: 31092386
MDS overlap disorders and diagnostic boundaries.
Tanaka TN, Bejar R
Blood 2019 Mar 7;133(10):1086-1095. Epub 2019 Jan 22 doi: 10.1182/blood-2018-10-844670. PMID: 30670443
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.
Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Stone RM, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Hoering A, Banerjee K, Chiarella M, Louie AC, Medeiros BC
J Clin Oncol 2018 Sep 10;36(26):2684-2692. Epub 2018 Jul 19 doi: 10.1200/JCO.2017.77.6112. PMID: 30024784Free PMC Article

Therapy

Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML.
Shimony S, Bewersdorf JP, Shallis RM, Liu Y, Schaefer EJ, Zeidan AM, Goldberg AD, Stein EM, Marcucci G, Lindsley RC, Chen EC, Ramos Perez J, Stein A, DeAngelo DJ, Neuberg DS, Stone RM, Ball B, Stahl M
Leukemia 2024 Apr;38(4):762-768. Epub 2024 Feb 20 doi: 10.1038/s41375-024-02175-0. PMID: 38378841
Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen: A Nonrandomized Controlled Trial.
Peyrl A, Chocholous M, Sabel M, Lassaletta A, Sterba J, Leblond P, Nysom K, Torsvik I, Chi SN, Perwein T, Jones N, Holm S, Nyman P, Mörse H, Öberg A, Weiler-Wichtl L, Leiss U, Haberler C, Schmook MT, Mayr L, Dieckmann K, Kool M, Gojo J, Azizi AA, André N, Kieran M, Slavc I
JAMA Oncol 2023 Dec 1;9(12):1688-1695. doi: 10.1001/jamaoncol.2023.4437. PMID: 37883081Free PMC Article
A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial.
Othman J, Wilhelm-Benartzi C, Dillon R, Knapper S, Freeman SD, Batten LM, Canham J, Hinson EL, Wych J, Betteridge S, Villiers W, Kleeman M, Gilkes A, Potter N, Overgaard UM, Mehta P, Kottaridis P, Cavenagh J, Hemmaway C, Arnold C, Dennis M, Russell NH
Blood Adv 2023 Aug 22;7(16):4539-4549. doi: 10.1182/bloodadvances.2023010276. PMID: 37171402Free PMC Article
MDS overlap disorders and diagnostic boundaries.
Tanaka TN, Bejar R
Blood 2019 Mar 7;133(10):1086-1095. Epub 2019 Jan 22 doi: 10.1182/blood-2018-10-844670. PMID: 30670443
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.
Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Stone RM, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Hoering A, Banerjee K, Chiarella M, Louie AC, Medeiros BC
J Clin Oncol 2018 Sep 10;36(26):2684-2692. Epub 2018 Jul 19 doi: 10.1200/JCO.2017.77.6112. PMID: 30024784Free PMC Article

Prognosis

Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution.
Rodriguez-Meira A, Norfo R, Wen S, Chédeville AL, Rahman H, O'Sullivan J, Wang G, Louka E, Kretzschmar WW, Paterson A, Brierley C, Martin JE, Demeule C, Bashton M, Sousos N, Moralli D, Subha Meem L, Carrelha J, Wu B, Hamblin A, Guermouche H, Pasquier F, Marzac C, Girodon F, Vainchenker W, Drummond M, Harrison C, Chapman JR, Plo I, Jacobsen SEW, Psaila B, Thongjuea S, Antony-Debré I, Mead AJ
Nat Genet 2023 Sep;55(9):1531-1541. Epub 2023 Sep 4 doi: 10.1038/s41588-023-01480-1. PMID: 37666991Free PMC Article
A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial.
Othman J, Wilhelm-Benartzi C, Dillon R, Knapper S, Freeman SD, Batten LM, Canham J, Hinson EL, Wych J, Betteridge S, Villiers W, Kleeman M, Gilkes A, Potter N, Overgaard UM, Mehta P, Kottaridis P, Cavenagh J, Hemmaway C, Arnold C, Dennis M, Russell NH
Blood Adv 2023 Aug 22;7(16):4539-4549. doi: 10.1182/bloodadvances.2023010276. PMID: 37171402Free PMC Article
Challenges in the diagnosis and treatment of secondary acute myeloid leukemia.
Ossenkoppele G, Montesinos P
Crit Rev Oncol Hematol 2019 Jun;138:6-13. Epub 2019 Mar 16 doi: 10.1016/j.critrevonc.2019.03.003. PMID: 31092386
MDS overlap disorders and diagnostic boundaries.
Tanaka TN, Bejar R
Blood 2019 Mar 7;133(10):1086-1095. Epub 2019 Jan 22 doi: 10.1182/blood-2018-10-844670. PMID: 30670443
CPX-351: changing the landscape of treatment for patients with secondary acute myeloid leukemia.
Talati C, Lancet JE
Future Oncol 2018 May;14(12):1147-1154. Epub 2018 Jan 30 doi: 10.2217/fon-2017-0603. PMID: 29378418

Clinical prediction guides

Discovery of U2AF1 neoantigens in myeloid neoplasms.
Biernacki MA, Lok J, Black RG, Foster KA, Cummings C, Woodward KB, Monahan T, Oehler VG, Stirewalt DL, Wu D, Rongvaux A, Deeg HJ, Bleakley M
J Immunother Cancer 2023 Dec 12;11(12) doi: 10.1136/jitc-2023-007490. PMID: 38164756Free PMC Article
Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution.
Rodriguez-Meira A, Norfo R, Wen S, Chédeville AL, Rahman H, O'Sullivan J, Wang G, Louka E, Kretzschmar WW, Paterson A, Brierley C, Martin JE, Demeule C, Bashton M, Sousos N, Moralli D, Subha Meem L, Carrelha J, Wu B, Hamblin A, Guermouche H, Pasquier F, Marzac C, Girodon F, Vainchenker W, Drummond M, Harrison C, Chapman JR, Plo I, Jacobsen SEW, Psaila B, Thongjuea S, Antony-Debré I, Mead AJ
Nat Genet 2023 Sep;55(9):1531-1541. Epub 2023 Sep 4 doi: 10.1038/s41588-023-01480-1. PMID: 37666991Free PMC Article
What is relative survival and what is its role in haematology?
Pohar Perme M, de Wreede LC, Manevski D
Best Pract Res Clin Haematol 2023 Jun;36(2):101474. Epub 2023 May 8 doi: 10.1016/j.beha.2023.101474. PMID: 37353298
Genetic changes during leukemic transformation to secondary acute myeloid leukemia from myeloproliferative neoplasms.
Kim T, Ahn JS, Son MH, Novitzky-Basso I, Yi SY, Ahn SY, Jung SH, Yang DH, Lee JJ, Choi SH, Lee JY, Moon JH, Sohn SK, Kim HJ, Zhang Z, Kim DDH
Leuk Res 2022 Jul;118:106858. Epub 2022 May 11 doi: 10.1016/j.leukres.2022.106858. PMID: 35609360
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.
Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Stone RM, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Hoering A, Banerjee K, Chiarella M, Louie AC, Medeiros BC
J Clin Oncol 2018 Sep 10;36(26):2684-2692. Epub 2018 Jul 19 doi: 10.1200/JCO.2017.77.6112. PMID: 30024784Free PMC Article

Recent systematic reviews

Overall survival and risk of second malignancies with cancer chemotherapy and G-CSF support.
Lyman GH, Yau L, Nakov R, Krendyukov A
Ann Oncol 2018 Sep 1;29(9):1903-1910. doi: 10.1093/annonc/mdy311. PMID: 30099478

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...